Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of 18F-fluoroestradiol (FES) Positron Emission Tomography (PET) on the Therapeutic Treatment of Metastatic Breast Cancer Patients, Initially ER Positive and HER2 Negative, in Relapse After First-line Therapy Combining Hormone Therapy

NCT05486182 is registered in ClinicalTrials.gov with GE Healthcare as lead sponsor.

NCT NCT05486182
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05486182 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of 18F-fluoroestradiol (FES) Positron Emission Tomography (PET) on the Therapeutic Treatment of Metastatic Breast Cancer Patients, Initially ER Positive and HER2 Negative, in Relapse After First-line Therapy Combining Hormone Therapy
Lead sponsor
GE Healthcare
Phase
Phase 4
Overall status
Active, not recruiting
Start date
February 8, 2022
Completion date
January 31, 2026
Enrollment
153 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer